<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Cardiac resynchronization therapy (CRT) benefits patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> and a wide QRS complex </plain></SENT>
<SENT sid="1" pm="."><plain>Still, one-third derive no clinical benefit and a majority of patients demonstrate no objective improvement of left ventricular (LV) function </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011713'>Left bundle branch block</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e>) is a strong predictor of response to CRT </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated whether absence of electrocardiogram (ECG) markers of residual left bundle (LB) conduction in guideline-defined <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> predicted a greater response to CRT </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: An r wave ≥1 mm in lead V1 (r-V1) and/or a q wave ≥1 mm in lead aVL (q-aVL) was used to identify patients with residual LB conduction </plain></SENT>
<SENT sid="5" pm="."><plain>Forty patients with a wide QRS were prospectively enrolled and subdivided into three groups: complete <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> (cLBBB), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> without r-V1 or q-aVL (n = 12); <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> with residual LB conduction (rLBBB), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> with r-V1 and/or q-aVL (n = 15); and non-specific <z:e sem="disease" ids="C0259758" disease_type="Disease or Syndrome" abbrv="">intraventricular conduction delay</z:e> (IVCD), (n = 13) </plain></SENT>
<SENT sid="6" pm="."><plain>Following CRT: mean change in left ventricular ejection fraction was 11.9 ± 11.9% in cLBBB, 3.8 ± 5.4% in rLBBB (P= 0.045), and 2.5 ± 4.4% in IVCD (P= 0.02 cLBBB vs. IVCD); mean reduction in left ventricular end-systolic volume was 26.4 ± 39.2% in cLBBB, 14.3 ± 22.9% in rLBBB (P= 0.35), and 5.6 ± 17.3% in IVCD (P= 0.11 cLBBB vs. IVCD); mean change in native QRS duration was -8.0 ± 11.0 ms in cLBBB, -0.8 ± 8.24 ms in rLBBB (P= 0.07), and 0.15 ± 8.0 ms in IVCD (P= 0.048 cLBBB vs. IVCD) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: In patients with guideline-defined <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e>, the absence of ECG markers of residual LB conduction was predictive of a greater improvement in LV function with CRT </plain></SENT>
</text></document>